Skip to content
The Policy VaultThe Policy Vault

Brukinsa (zanubrutinib capsules and tablets) — Cigna

Marginal Zone Lymphoma

Initial criteria

  • Patient age ≥ 18 years
  • Patient has tried at least one systemic regimen

Approval duration

1 year